The current risk of retroviral infections transmitted by transfusion in patients who have undergone multiple transfusions

Archives of Internal Medicine

Volumn 158, Issue 14, 1998, Pages 1566-1569

  Prati, Daniele ^a   Capelli, Carmen ^a   Rebulla, Paolo ^a   Mozzi, Fulvio ^a   Bosoni, Patrizia ^a   De Mattei, Claudia ^a   Sirchia, Girolamo ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CHILD; COHORT ANALYSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS; INFANT; INFECTION RATE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELIABILITY; RETROVIRUS; RISK ASSESSMENT; SCREENING; SEROCONVERSION; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; DELTARETROVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INFANT; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; RISK;

EID: 0031872583     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.14.1566     Document Type: Article

References (26)

1. Selik RM, Ward JW, Bueheler JW. Trends in transfusion-associated acquired immune deficiency syndrome in the United States, 1982 through 1991. Transfusion. 1993;33:890-893.
2. Zaaijer HL, v Exel-Oehlers P, Kraaijeveld T, Altena E, Lelie PN. Early detection of antibodies to HIV-1 by third-generation assays. Lancet. 1992;340:770-772.
3. Busch MP, Lee LL, Satten GA, et al. Time course of detection of viral and serological markers preceding HIV-1 seroconversion: implication for blood and tissue donor screening. Transfusion. 1995;35:91-97.
4. Loussert-Ajaka I, Ly TD, Chaix ML, et al. HIV-1/HIV-2 seronegativity in HIV-1 subtype 0 infected patients. Lancet. 1994;343:1393-1394.
5. Nkengasong JN, Peelers M, Vanden Haesevelde M, et al. Antigenic evidence of the presence of the aberrant HIV-1 ANT-70 virus in Cameroon and Gabon. AIDS. 1993;7:1536-1538.
6. Lackritz EM, Satten GA, Aberle-Grasse J, et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med. 1995;333:1721-1725.
7. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ, for the Retrovirus Epidemiology Donor Study. The risk of transfusion-transmitted infections. N Engl J Med. 1996;334:1685-1690.
8. Bazarbachi A, Huang M, Gessain A, et al. Human T-cell-leukemia virus type I in post-transfusional spastic paraparesis: complete proviral sequence from uncultured blood cells. Int J Cancer. 1995;63:494-499.
9. Kamihira S, Nakasima S, Oyakawa Y, et al. Transmission of human T-cell lymphotropic virus type I by blood transfusion before and after mass screening of sera from seropositive donors. Vox Sang. 1987;52:43-44.
10. Rebulla P, Modell B. Transfusion requirements and effects in patients with thalassaemia major. Lancet. 1991;337:277-280.
11. Mozzi F, Rebulla P, Lillo F, et al, for the Cooleycare Cooperative Group. HIV and HTLV infections in 1305 transfusion-dependent thalassemics in Italy [published correction appears in AIDS. 1992;6:606]. AIDS. 1992;6:505-508.
12. Nelson KE, Donahue JG, Muñoz A, et al. Transmission of retroviruses from seronegative donors by transfusion during cardiac surgery: a multicenter study of HIV-1 and HTLV-I/II infections. Ann Intern Med. 1992;117:554-559.
13. Operskalski EA, Stram DO, Lee H, et al. Human immunodeficiency virus-1 infection: relationship of risk group and age to rate of progression to AIDS. J Infect Dis. 1995;172:648-655.
14. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet. 1989;2:27-30.
15. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med. 1994;331:574-578.
16. Lefrere JJ, Girot R. HIV infection in pofytransfused thalassemic patients. Lancet. 1987;2:686.
17. Petersen LR, Satten GA, Dodd R, et al. Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody: the HIV Seroconversion Study Group. Transfusion. 1994;34:283-289.
18. Busch MP, Young MJ, Samson SM, Mosley JW, Ward JW, Perkins HA. Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening: the Transfusion Safety Study Group. Transfusion. 1991;31:4-11.
19. Dodd RY. The risk of transfusion transmitted infection. N Engl J Med. 1992;327: 419-421.
20. Leitman SF, Klein HG, Melpolder JJ, et al. Clinical implications of positive test for antibodies to human immunodeficiency virus type I in asymptomatic blood donors. N Engl J Med. 1989;321:917-924.
21. Perkins HA, Samson S, Busch MP. How well has self-exclusion worked? Transfusion. 1988;28:601-602.
22. Jason JM, McDougal JS, Cabradilla C, Kalyanaraman VS, Evatt BL. Human T-cell leukemia virus (HTLV-I) p 24 antibody in New York City blood product recipients. Am J Hematol. 1985;20:129-137.
23. Chorba TL, Jason JM, Ramsey RB, et al. HTLV-I antibody status in hemophilia patients treated with factor concentrates prepared from US plasma sources and in hemophilia patients with AIDS. Thromb Haemost. 1985;53:180-182.
24. Zehender G, Girotto M, De Maddalena C, Francisco G, Moroni M, Galli M. HTLV infection in ELISA-negative blood donors. AIDS Res Hum Retroviruses. 1996; 12:737-740.
25. Rebulla P. Blood transfusion in β thalassaemia major. Transfus Med. 1995;5: 247-258.
26. Bordin JO, Heddle NM, Blajchman MA. Biologic effects of leukocytes present in transfused cellular blood products. Blood. 1994;84:1703-1721.